{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:40:30Z","timestamp":1790484030944,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA-036398"],"award-info":[{"award-number":["DA-036398"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS-090629"],"award-info":[{"award-number":["NS-090629"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"The National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH-65099"],"award-info":[{"award-number":["MH-65099"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Many original research articles have been published that describe findings and outline areas for the development of kappa-opioid agonists (KOAs) as novel drugs; however, a single review article that summarizes the broad potential for KOAs in drug development does not exist. It is well-established that KOAs demonstrate efficacy in pain attenuation; however, KOAs also have proven to be beneficial in treating a variety of novel but often overlapping conditions including cardiovascular disease, pruritus, nausea, inflammatory diseases, spinal anesthesia, stroke, hypoxic pulmonary hypertension, multiple sclerosis, addiction, and post-traumatic cartilage degeneration. This article summarizes key findings of KOAs and discusses the untapped therapeutic potential of KOAs in the treatment of many human diseases.<\/jats:p>","DOI":"10.3390\/ph12020095","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:49:59Z","timestamp":1561027799000},"page":"95","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Therapeutic Potential of Kappa Opioid Agonists"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-8943","authenticated-orcid":false,"given":"Tyler C.","family":"Beck","sequence":"first","affiliation":[{"name":"Drug Discovery &amp; Biomedical Sciences, Medical University of South Carolina, 280 Calhoun Street, QF204, Charleston, SC 29424-2303, USA"},{"name":"College of Medicine, 173 Ashley Ave., Charleston, SC 29424-2303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Hapstack","sequence":"additional","affiliation":[{"name":"College of Medicine, 173 Ashley Ave., Charleston, SC 29424-2303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle R.","family":"Beck","sequence":"additional","affiliation":[{"name":"College of Pharmacy, The Ohio State University, 500 W 12th Ave, Columbus, OH 43210-9998, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9387-1689","authenticated-orcid":false,"given":"Thomas A.","family":"Dix","sequence":"additional","affiliation":[{"name":"Drug Discovery &amp; Biomedical Sciences, Medical University of South Carolina, 280 Calhoun Street, QF204, Charleston, SC 29424-2303, USA"},{"name":"JT Pharmaceuticals, Inc., 300 West Coleman Blvd., Suite 203, Mount Pleasant, SC 29464-2303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular Mechanisms of Opioid Receptor-dependent Signaling and Behavior","volume":"115","author":"Bruchas","year":"2011","journal-title":"Anesthesiology"},{"key":"ref_2","unstructured":"(2019, February 22). Annual Surveillance Report of Drug-Related Risks and Outcomes\u2014United States, 2017. Surveillance Special Report: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Available online: https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2017-cdc-drug-surveillance-report.pdf."},{"key":"ref_3","unstructured":"(2019, February 19). Opioid Overdose, Available online: https:\/\/www.cdc.gov\/drugoverdose\/data\/prescribing.html."},{"key":"ref_4","unstructured":"Bree, D. (2019, February 19). The Kappa Opioid Receptor Takes Shape. Available online: https:\/\/www.painresearchforum.org\/news\/93114-kappa-opioid-receptor-takes-shape."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/1381612043453036","article-title":"Peripheral restricted opioid agonists and novel analgesic agents","volume":"10","author":"Dolle","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","unstructured":"(2019, February 19). Opioid Overdose: Understanding the Epidemic, Available online: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"172396","DOI":"10.1016\/j.ejphar.2019.05.025","article-title":"Non-addictive orally-active kappa opioid agonist for the treatment of peripheral pain","volume":"856","author":"Beck","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.brainresrev.2008.12.017","article-title":"Peripheral mechanisms of pain and analgesia","volume":"60","author":"Stein","year":"2008","journal-title":"Brain Res. Rev."},{"key":"ref_9","first-page":"145965","article-title":"Effects of Combined Opioids on Pain and Mood in Mammals","volume":"2012","author":"Rech","year":"2012","journal-title":"Pain Res. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.11.028","article-title":"Multitarget opioid ligands in pain relief: New players in an old game","volume":"108","author":"Turnaturi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1874104501307010016","article-title":"Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain","volume":"7","author":"Hughes","year":"2013","journal-title":"Open Med. Chem. J."},{"key":"ref_12","unstructured":"(2019, February 22). Pharmaceutical Product Development for Pruritus & Pain. Available online: https:\/\/www.caratherapeutics.com\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics\u20142017 Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"ref_14","first-page":"S430","article-title":"Burden of Disease: Medical and Economic Impact of Acute Coronary Syndromes","volume":"12","author":"Turpie","year":"2006","journal-title":"Am. J. Manag. Care"},{"key":"ref_15","unstructured":"Zafari, M. (2019, March 10). Myocardial Infarction Treatment & Management. Available online: https:\/\/emedicine.medscape.com\/article\/155919-treatment."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamacardio.2016.0074","article-title":"Atherosclerotic Burden and Heart Failure After Myocardial Infarction","volume":"1","author":"Gerber","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00380-013-0456-5","article-title":"The presence of mu-, delta- and kappa-opioid receptors in human heart tissue","volume":"29","author":"Sobanski","year":"2014","journal-title":"Heart Vessels"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.2174\/1381612820666140204120311","article-title":"Opioid-Induced Cardioprotection","volume":"20","author":"Tanaka","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005344-200403000-00012","article-title":"Effect of Exogenous Kappa-Opioid Receptor Activation in Rat Model of Myocardial Infarction","volume":"43","author":"Peart","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1159\/000447911","article-title":"Kappa-Opioid Agonist U50,488-Mediated Protection Against Heart Failure Following Ischemia\/Reperfusion: Dual Roles of Heme Oxygenase","volume":"39","author":"Tong","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cyto.2013.01.002","article-title":"\u03ba-Opioid Receptor Stimulation Modulates TLR4\/NF-\u03baB signaling in the Rat Heart Subjected to Ischemia-Reperfusion","volume":"61","author":"Lin","year":"2013","journal-title":"Cytokine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1440-1681.1999.03143.x","article-title":"Pro- and Anti-Arrhythmic Effects of a \u03ba-Opioid Receptor Agonist: A Model for the Biphasic Action of a Local Hormone in the Heart","volume":"26","author":"Yu","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1527-3458.2003.tb00248.x","article-title":"A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist","volume":"9","author":"Wadenberg","year":"2003","journal-title":"CNS Drug Rev."},{"key":"ref_24","unstructured":"Rosenson, R.S., Reeder, G.S., and Kennedy, H.L. (2019). Acute myocardial infarction: Role of beta blocker therapy. UpToDate, Available online: https:\/\/www.uptodate.com\/contents\/acute-myocardial-infarction-role-of-beta-blocker-therapy."},{"key":"ref_25","first-page":"30","article-title":"Pruritus: An Updated Look on an Outdated Problem","volume":"2","author":"Tivoli","year":"2009","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of Pruritus with Topically Applied Opiate Receptor Anatagonist","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","unstructured":"(2019, April 11). Burden of Disease: Chronic Inflammation and Inflammatory Disease. Available online: https:\/\/www.pfizer.com\/sites\/default\/files\/health\/VOM_Chronic_Inflammation_and_Inflammatory_Diseases.pdf."},{"key":"ref_28","first-page":"148","article-title":"Anti-Inflammatory Effects of Opioids","volume":"521","author":"Walker","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jp.2012.124","article-title":"Opioids and clonidine modulate cytokine production and opioid receptor expression in neonatal immune cells","volume":"33","author":"Kovell","year":"2013","journal-title":"J. Perinatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.4049\/jimmunol.164.10.5088","article-title":"\u03ba-Opioid Regulation of Thymocyte IL-7 Receptor and C-C Chemokine Receptor 2 Expression","volume":"164","author":"Zhang","year":"2000","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1182\/blood-2007-12-129122","article-title":"Anti-inflammatory effects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modulation of CCL21-triggered integrin-mediated adhesions","volume":"112","author":"Flaishon","year":"2008","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0304-3959(90)90054-H","article-title":"Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia","volume":"43","author":"Joris","year":"1990","journal-title":"Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-12-801284-0.00005-1","article-title":"Functions of the Chemokine Receptor CXCR4 in the Central Nervous System and Its Regulation by u-Opioid Receptors","volume":"118","author":"Nash","year":"2014","journal-title":"Neuroimmune Signal. Drug Actions Addict. Int. Rev. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cellimm.2007.09.008","article-title":"Opioid and Nociceptin Receptors Regulate Cytokine and Cytokine Receptor Expression","volume":"252","author":"Finley","year":"2008","journal-title":"Cell. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1053\/j.gastro.2003.09.040","article-title":"Nausea and vomiting","volume":"125","author":"Hasler","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(86)90760-0","article-title":"Emetic and antiemetic effects of opioids in the dog","volume":"128","author":"Blancquaert","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-6576.2009.02115.x","article-title":"The potential for mu-opioid receptor agonists to be anti-emetic in humans: A review of clinical data","volume":"54","author":"Johnston","year":"2010","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1526-4637.2009.00583.x","article-title":"Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chronic Pain: Mechanisms, Implications, and Management Options","volume":"10","author":"Porreca","year":"2009","journal-title":"Pain Med."},{"key":"ref_39","unstructured":"Miller, R.D., Eriksson, L.I., Fleisher, L.A., Wiener-Kronish, J.P., and Young, W.L. (2009). Miller\u2019s Anesthesia, Churchill Livingstone. [7th ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/00000539-200012000-00029","article-title":"The Use of Bupivicaine and Fentanyl for Spinal Anesthesia for Urologic Surgery","volume":"91","author":"Kuusniemi","year":"2000","journal-title":"Anesth. Analg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0970-9185.117045","article-title":"Neuraxial Opioid-Induced Pruritus: An Update","volume":"29","author":"Kumar","year":"2013","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/AAP.0000000000000382","article-title":"Species Variaion in effects of Intrathecal K-Opioid Receptor Agonist on Morphine-Induced Itch and Antinociception","volume":"41","author":"Ruan","year":"2016","journal-title":"Reg. Anesth. Pain Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0361-9230(86)90056-0","article-title":"Kappa opioid receptors in human lumbo-sacral spinal cord","volume":"16","author":"Kopp","year":"1986","journal-title":"Brain Res. Bull."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.neuroscience.2003.12.042","article-title":"Kappa opioid receptors in rat spinal cord: Sex-linked distribution differences","volume":"124","author":"Harris","year":"2004","journal-title":"Neuroscience"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1213\/00000539-198604000-00007","article-title":"Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression","volume":"65","author":"Castillo","year":"1986","journal-title":"Anesth. Analg."},{"key":"ref_46","first-page":"631","article-title":"The Kappa Opioid Agonist U-50,488H Antagonizes Respiratory Effects of Mu Opioid Receptor Agonists in Conscious Rats","volume":"264","author":"Tortella","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","unstructured":"(2019, April 07). The Internet Stroke Center. Available online: http:\/\/www.strokecenter.org\/patients\/about-stroke\/stroke-statistics\/."},{"key":"ref_48","unstructured":"(2019, April 07). Stroke Treatment. Available online: http:\/\/www.strokeassociation.org\/STROKEORG\/AboutStroke\/Treatment\/Stroke-Treatment_UCM_492017_SubHomePage.jsp."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.STR.0000072512.30658.E7","article-title":"Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats","volume":"34","author":"Goyagi","year":"2003","journal-title":"Stroke"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0006-8993(87)90121-1","article-title":"Protection from ischemia-induced cerebral edema in the rat by U-50488H, a kappa opioid receptor agonist","volume":"403","author":"Silvia","year":"1987","journal-title":"Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1161\/01.STR.0000125011.93188.c6","article-title":"Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats","volume":"35","author":"Chen","year":"2004","journal-title":"Stroke"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brainres.2011.01.083","article-title":"Opioid receptor agonists reduce brain edema in stroke","volume":"1383","author":"Yang","year":"2011","journal-title":"Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2018.05.025","article-title":"Quaternary ammonium salt of U50,488H elicits protective effects against hypoxic pulmonary hypertension","volume":"832","author":"Zhou","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_54","unstructured":"(2019, May 10). Multiple Sclerosis FAQs. Available online: https:\/\/www.nationalmssociety.org\/What-is-MS\/MS-FAQ-s - question-What-is-multiple-sclerosis."},{"key":"ref_55","unstructured":"(2019, May 10). MS Facts and Data. Available online: https:\/\/multiplesclerosis.net\/what-is-ms\/statistics\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1523\/JNEUROSCI.1493-16.2016","article-title":"Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination","volume":"36","author":"Mei","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_57","unstructured":"(2019, May 11). Treatment Approaches for Drug Addiction: National Institute on Drug Abuse, Available online: https:\/\/www.drugabuse.gov\/publications\/drugfacts\/treatment-approaches-drug-addiction."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","article-title":"U50,488, a \u03ba opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats","volume":"181","author":"Maisonneuve","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/syn.10005","article-title":"Major co-expression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles","volume":"42","author":"Svingos","year":"2001","journal-title":"Synapse"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9333","DOI":"10.1523\/JNEUROSCI.20-24-09333.2000","article-title":"Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine","volume":"20","author":"Thompson","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-420118-7.00012-3","article-title":"Salvinorin A analogs and other kappa opioid receptor compounds as treatments for cocaine abuse","volume":"69","author":"Kivell","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"ref_62","unstructured":"(2019, May 13). Osteoarthritis. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/osteoarthritis\/symptoms-causes\/syc-20351925."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e88553","DOI":"10.1172\/jci.insight.88553","article-title":"Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration","volume":"2","author":"Wu","year":"2017","journal-title":"JCI Insight"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00000542-200106000-00018","article-title":"Analgesic and Antiinflammatory Effects of Two Novel \u03ba-Opioid Peptides","volume":"94","author":"Binder","year":"2001","journal-title":"Anesthesiology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: Current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0008-6363(99)00112-1","article-title":"Opioid peptides and the heart","volume":"43","author":"Barron","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.yjmcc.2009.06.016","article-title":"Kappa and delta opioid receptor signaling is augmented in the failing heart","volume":"47","author":"Bolte","year":"2009","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","article-title":"Inflammation, Immune Activation, and Antiretroviral Therapy in HIV","volume":"14","author":"Hileman","year":"2017","journal-title":"Curr. HIV\/AIDS Rep."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/95\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:59:51Z","timestamp":1760187591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/2\/95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ph12020095"],"URL":"https:\/\/doi.org\/10.3390\/ph12020095","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}